Hemab Therapeutics (NASDAQ:COAG) Major Shareholder Purchases $37,045.34 in Stock

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) major shareholder Ra Capital Management, L.P. acquired 1,483 shares of the company’s stock in a transaction dated Friday, May 8th. The shares were bought at an average price of $24.98 per share, for a total transaction of $37,045.34. Following the purchase, the insider owned 6,325,914 shares in the company, valued at approximately $158,021,331.72. This represents a 0.02% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, May 11th, Ra Capital Management, L.P. purchased 39,869 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $24.81 per share, for a total transaction of $989,149.89.
• On Thursday, May 7th, Ra Capital Management, L.P. purchased 9,906 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $24.46 per share, for a total transaction of $242,300.76.
• On Wednesday, May 6th, Ra Capital Management, L.P. purchased 68,018 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $24.60 per share, for a total transaction of $1,673,242.80.
• On Tuesday, May 5th, Ra Capital Management, L.P. purchased 97,411 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $24.63 per share, for a total transaction of $2,399,232.93.
• On Monday, May 4th, Ra Capital Management, L.P. purchased 2,675,000 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $18.00 per share, for a total transaction of $48,150,000.00.

Hemab Therapeutics Price Performance

COAG opened at $28.56 on Thursday. Hemab Therapeutics Holdings, Inc. has a 1-year low of $23.00 and a 1-year high of $36.61.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.